首页> 美国卫生研究院文献>Clinical Ophthalmology (Auckland N.Z.) >Efficacy and safety of olopatadine hydrochloride 0.77 in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

【2h】

Efficacy and safety of olopatadine hydrochloride 0.77 in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

机译：结膜变应原激发模型对盐酸奥洛他定0.77％过敏性结膜炎的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundSymptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis.

机译：背景治疗后24小时内症状缓解将使过敏性结膜炎患者受益。

著录项

期刊名称 Clinical Ophthalmology (Auckland N.Z.)
作者
Gail Torkildsen; Abhijit Narvekar; Mark Bergmann;
展开▼
作者单位

展开▼
年(卷),期 2015(9),-1
年度 2015
页码 1703–1713
总页数 11
原文格式 PDF
正文语种
中图分类眼科学;
关键词
allergic conjunctivitis allergic rhinoconjunctivitis ocular inflammation antihistamine conjunctival allergen-challenge (CAC) model high-concentration olopatadine;

机译：变应性结膜炎;变应性鼻结膜炎;眼部炎症;抗组胺药;结膜变应原攻击（CAC）模型;高浓度奥洛他定;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model [J] . Gail Torkildsen, Abhijit Narvekar, Mark Bergmann Clinical ophthalmology . 2015,第5期

机译：结膜变应原挑战模型对盐酸奥洛他定0.77％过敏性结膜炎的疗效和安全性
2. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model [J] . McLaurin Eugene, Narvekar Abhijit, Gomes Paul, Cornea . 2015,第10期

机译：使用结膜变应原激发模型对每日一次0.77％盐酸奥洛他定盐酸盐滴眼液在过敏性结膜炎患者中的功效和安全性进行的3期随机双层掩盖研究
3. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis [J] . Eugene McLaurin, Mark Bergmann, Abhijit Narvekar, Clinical ophthalmology . 2017,第9期

机译：两项研究评估盐酸奥洛他定0.77％对过敏性结膜炎的疗效和安全性的汇总研究
4. EFFICACY OF NIFEKALANT HYDROCHLORIDE ON THEMANAGEMENT OF LIFE-THREATENING VENTRICULARTACHYARRHYTHMIAS IN PATIENTS WITH NON-ISCHEMICCARDIOMYOPATHY. [C] . TAKASHI WASHI UK International Congress on Electrocardiology . 2005

机译：NiFekalant Nifekalant盐酸疗效对非缺血性心肌病患者危及危及危及心室性心律失常的疗效。
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77 in patients with allergic conjunctivitis [O] . Eugene McLaurin, Mark Bergmann, Abhijit Narvekar, 2017

机译：两项研究评估了盐酸奥洛他定0.77％对过敏性结膜炎的疗效和安全性的汇总研究
7. Efficacy and safety of olopatadine hydrochloride 0.77 in patients with allergic conjunctivitis using a conjunctival allergen-challenge model [O] . Gail Torkildsen, Abhijit Narvekar, Mark Bergmann 2015

机译：使用结膜过敏原 - 挑战模型的过敏性结膜炎患者盐酸盐酸盐的疗效和安全性0.77％

Efficacy and safety of olopatadine hydrochloride 0.77 in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

摘要

著录项

相似文献

相关主题

期刊订阅